Remimazolam for Bronchoscopy in High-Risk Patients
A Prospective, Randomized Controlled Clinical Study of the Effect of Remimazolam on the Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Yeke Zhu
- Phone Number: +8613515815457
- Email: 21618018@zju.edu.cn
Study Contact Backup
- Name: Yueying Zheng
- Phone Number: +8613777408863
- Email: 1507128@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- the First Affliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Phone Number: +8613515815457
- Email: 21618018@zju.edu.cn
-
Shaoxing, Zhejiang, China, 310000
- Not yet recruiting
- Shaoxing City First People's Hospital
-
Contact:
- Zhonghua Chen
- Phone Number: +8613867502391
- Email: 841135078@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ASA Class Ⅲ - Ⅳ
- Scheduled for elective painless bronchoscopy -
Exclusion Criteria:
- Age < 18 years
- Patients who are uncooperative(e.g. due to mental illness)
- Patients who are on chronic use of opioids, benzodiazepine - class hypnotics, or antidepressants
- Patients with a history of allergy to the anesthetics used
- Patients who are anticipated to have a difficult airway
- Body mass index(BMI)<18.5kg/m² or >30kg/m²
- Preoperative oxygen saturation <92% while breathing room air
- Other:Patients who are deemed by the investigator to be unsuitable for participation in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: The propofol - alfentanil group(The control group)
In this group, general anesthesia was administered using the classic propofol and alfentanil.
The patients underwent fiberoptic bronchoscopy while maintaining spontaneous breathing and with a MOAA/S score of ≤2.
|
General anesthesia with spontaneous breathing maintained is administered using propofol and alfentanil.
|
|
Experimental: The remimazolam and propofol - alfentanil group (The experimental group)
This group received general anesthesia with remimazolam combined with propofol for sedation and alfentanil.
Fiberoptic bronchoscopy was done while patients maintained spontaneous breathing and had a MOAA/S score of ≤2.
|
General anesthesia with spontaneous breathing maintained is administered using remimazolam combined with propofol and alfentanil.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of hypoxia(75% ≤ SpO2 < 90% for <60 s)
Time Frame: Periprocedural
|
Periprocedural
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of severe hypoxia(SpO2 < 75% or 75% ≤ SpO2 < 90% for ≥60 s)
Time Frame: Periprocedural
|
Periprocedural
|
|
Non-Invasive Blood Pressure changes: The area under the curve (AUC) of the patient's mean blood pressure over time from pre-anesthesia induction to the end of bronchoscopy during patient monitoring
Time Frame: Periprocedural
|
Periprocedural
|
|
The area under the curve (AUC) of the patient's mean blood pressure during observation in Post-Anesthesia Care Unit
Time Frame: Periprocedural
|
Periprocedural
|
|
The dosage of vasoactive drugs administered.
Time Frame: Periprocedural
|
Periprocedural
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of other adverse events
Time Frame: Periprocedural
|
Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force
|
Periprocedural
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Signs and Symptoms, Respiratory
- Gram-Positive Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hypoxia
- Tuberculosis, Pulmonary
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Piperidines
- Phenols
- Benzene Derivatives
- Fentanyl
- Propofol
- Alfentanil
Other Study ID Numbers
Other Study ID Numbers
- ZJU2026B0127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.